|Year : 2018 | Volume
| Issue : 1 | Page : 7-18
The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes
Hamzah Abu-Sbeih1, Tenglong Tang1, Faisal Shaukat Ali1, Daniel Hartman Johnson2, Wei Qiao3, Adi Diab2, Yinghong Wang1
1 Department of Gastroenterology, Hepatology and Nutrition, Houston, Texas, USA
2 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
|Date of Web Publication||31-Jul-2018|
Dr. Yinghong Wang
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas md Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1466, Houston, Texas 77030
Source of Support: None, Conflict of Interest: None
Background: Immune checkpoint inhibitors (ICPIs) are gaining more popularity as a treatment for advanced cancers. However, immune-related adverse events (irAEs) limit their use. We aimed to assess the impact of irAEs and their treatment on clinical and survival outcomes. Materials and Methods: We retrospectively reviewed records of the patients who received ICPIs between 2011 and 2017. Descriptive analyses were employed to compare different groups. Kaplan–Meier curves and log-rank tests were used to estimate and compare overall survival durations. Results: Of 427 identified patients, 202 (47.3%) had one or more irAEs. Overall, the patients who developed irAEs had better overall survival than did patients with no-irAEs, regardless of immunosuppressant treatment (P < 0.01). Patients with mild irAEs who did not require immunosuppressive treatment had longer overall survival duration than did patients without irAEs (P < 0.01). Patients with three or more irAEs had longer median overall survival compared to patients with two or less irAEs (P = 0.01). Infliximab was associated with shorter duration of steroid use as compared to steroid treatment only (2 months [standard deviation (SD), 8] vs. 4 months [SD, 4]). Steroid treatment for >30 days was associated with higher rate of infections compared to shorter duration (P = 0.03). Conclusion: IrAEs are associated with favorable overall survival, regardless of immunosuppression treatment requirement. IrAEs involving multiple organs appeared to be beneficial for overall survival. Early infliximab use shortens the duration of steroid treatment and therefore balances better cancer outcomes with decreased risk of infection.
Keywords: Adverse events, immune checkpoint inhibitor, immunosuppressive treatment, immunotherapy, impact, survival, toxicities
|How to cite this article:|
Abu-Sbeih H, Tang T, Ali FS, Johnson DH, Qiao W, Diab A, Wang Y. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes. J Immunother Precis Oncol 2018;1:7-18
|How to cite this URL:|
Abu-Sbeih H, Tang T, Ali FS, Johnson DH, Qiao W, Diab A, Wang Y. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes. J Immunother Precis Oncol [serial online] 2018 [cited 2019 Nov 22];1:7-18. Available from: http://www.jipoonline.org/text.asp?2018/1/1/7/237827
| Introduction|| |
Immune checkpoint inhibitors (ICPIs) have been a treatment option for patients with advanced cancers since the first agent, ipilimumab, was approved for clinical use by the United States Food and Drug Administration in 2011. ICPIs destroy tumor cells by inhibiting proteins that allow tumor cells to evade detection by T-cells, including programmed death protein 1 (PD-1), PD-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), thereby reactivating cytotoxic T-cells. ICPIs have been proven to significantly improve overall survival and delay tumor progression in patients with melanoma, nonsmall cell lung cancer, and other types of cancers.,,,,,,
Despite the success of these drugs, ICPI treatment still has challenges and limitations. Immune-related adverse events adverse events (irAEs) require early recognition and prompt treatment. IrAEs can involve a wide variety of organs, most commonly the skin, gastrointestinal (GI) tract, liver, lung, and endocrine system, and can cause moderate symptoms or severe complications and even death. GI tract toxicities, including diarrhea and colitis, are the second most common irAEs.,,,,, Therefore, a detailed understanding of the characteristics of GI tract irAEs is essential.
Because irAEs are autoimmune, immunosuppression with steroids is commonly the first-line treatment. For patients whose symptoms respond inadequately or don't respond to steroid therapy to steroid therapy and those who suffer severe steroid-related adverse events, other immunosuppressive agents are used, such as the tumor necrosis factor-alpha inhibitor infliximab. With appropriate and timely treatment, most irAEs can be substantially reversed.
Researchers continue to debate whether the occurrence of irAEs is an indicator of favorable tumor response to ICPI treatment., However, lengthy immunosuppressive treatment may hamper the enhancing effect of ICPI treatment on patients' immune systems, weakening the immune attack on the tumor, and raising the risk of infection. These contradictory effects should be taken into account when managing irAEs with immunosuppressive treatment. Definitive evidence regarding the association of irAEs, complications related to immunosuppressive treatment of irAEs, and tumor response to ICPIs is lacking as is the evidence for how irAEs affect overall survival.
In this retrospective study, we aimed to describe the characteristics and treatment of patients at a tertiary-care cancer center who developed irAEs following anti-PD-1/PD-L1, anti-CTLA-4, or combination ICPI therapy for solid and hematological malignancies. We also aimed to determine the impact of various patient- and ICPI-related factors, including the characteristics of irAEs, on overall survival.
| Materials and Methods|| |
Study design and population
This retrospective, descriptive, single-center study was conducted with approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center. Included patients (1) were 18 years of age or older, (2) had an established diagnosis of solid or hematological malignancy, and (3) received single- or multiple-agent ICPI therapy between March 2011 and March 2017.
Patient information and data relating to ICPI treatment and irAEs were extracted from electronic medical records and our institutional pharmacy database. We collected information on patient demographics, medical history, cancer-related variables, ICPI regimen (s), irAEs, irAE treatment, infectious adverse events related to irAE treatment, and the date of death or last contact. Patient demographics consisted of age, sex, and race/ethnicity. Variables pertaining to medical history included concomitant morbidities, lifetime smoking history, and nonsteroidal anti-inflammatory drug (NSAID) use within 3 months of ICPI initiation. Concomitant morbidities were recorded from a review of medical records, diagnostic laboratory studies, and histopathology reports. Reported comorbidities included hypertension, diabetes mellitus, dyslipidemia, hypocortisolism, chronic obstructive pulmonary disease, asthma, coronary artery disease, congestive heart failure, atrial fibrillation, HIV infection, GI graft versus host disease, and autoimmune diseases (celiac disease, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, connective tissue disease, sarcoidosis, Sjögren's syndrome, and Hashimoto thyroiditis).
Oncological details collected included the type, site, and stage of cancer. Cancer type was categorized as hematological malignancy, melanoma, or solid tumor. Because melanoma was the only skin malignancy reported, we considered melanoma instead of skin tumor as a distinct category. The stage of melanoma and solid tumors was reported according to the American Joint Committee on Cancer staging system 7th edition. The stage of hematological malignancies was not reported. ICPIs used included ipilimumab, nivolumab, pembrolizumab, and atezolizumab. The ICPI regimen was classified as “combination” if the patient received both nivolumab and ipilimumab during the same treatment course. Overall survival duration was measured from the time of first ICPI dose to the time of death or last clinical encounter for patients who were still alive.
IrAEs were categorized on the basis of the involved organ(s) as diarrhea/colitis, hepatitis, pneumonitis, endocrine dysfunction, dermatitis, and anemia. The number of organs involved was recorded for each patient. The grade of diarrhea and colitis, determined using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03, was extracted from the electronic medical records at the time of initial presentation. For non-GI irAEs, only events of Grade 2 or higher were recorded. The immunosuppressive agent(s) used for the treatment of irAEs were steroids and infliximab. In our study population, the symptoms of all the patients who received infliximab were refractory to steroid treatment; therefore, all patients who received infliximab also received steroids. The duration of steroid treatment was measured from the time of steroid therapy initiation at the time of irAE diagnosis to the cessation of steroid treatment or return to the previous baseline dosage received as part of the cancer treatment regimen. In addition, we categorized the duration of steroid treatment as “long” if it was >30 days or “short” if it was 30 days or fewer. Information on infections that occurred at any time from the beginning of steroid treatment through 1 month after the discontinuation of immunosuppressive treatment was extracted from medical records and diagnostic laboratory studies. We categorized types of infection on the basis of the organ involved and/or the inciting organism.
Statistical analysis was performed using SPSS Statistics software (version 24.0; IBM Corporation, Armonk, NY, USA). We summarized the distribution of the data using descriptive statistics: means and standard deviations for continuous variables; frequencies and percentages for categorical variables. Continuous variables were compared using the Wilcoxon ranked-sum test. The Fisher's exact test or the Chi-square test was conducted to evaluate associations between categorical variables. Multivariate logistic regression analysis was performed to assess for independent associations between factors found to be significant in the univariate analysis and the development of irAE(s) or infection. Kaplan–Meier curves were used to estimate unadjusted overall survival durations. Log-rank tests were used to compare overall survival durations between groups. All statistical tests were two-sided. P <0.05 was considered statistically significant.
| Results|| |
A total of 427 patients were included in this analysis between March 2011 and March 2017. Among them, 202 patients had either single or multiple irAEs, and 225 patients had no irAE. A total of 117 (27.4%) patients had ICPI-related diarrhea and/or colitis.
Immune-related adverse events
Clinical characteristics of patients who had irAEs and those who did not have irAEs are compared in [Table 1]. Patients with irAEs received ICPI treatment for shorter duration than did patients without irAEs (81 days vs. 112 days, P = 0.018). No differences were found between the two groups in age, sex, smoking history, concomitant autoimmune disease, multiple comorbidities, NSAID, or immunosuppressant use within 3 months of ICPI initiation.
|Table 1: Demographic and clinical characteristics of patients with and without immune checkpoint inhibitor-related adverse events|
Click here to view
A single irAE occurred in 126/202 (62.4%) patients, and multiple irAEs occurred in 76/202 (37.6%) patients [Table 2]. Diarrhea/colitis was observed in 64/126 (50.8%) patients as a single irAE and in 53/76 (69.7%) patients as one of the multiple irAEs. Pneumonitis was the most commonly reported non-GI irAE (n = 42, 20.8%). The type of immunosuppressive treatment, duration of treatment, and rate of associated infections were comparable between the single- and multiple-irAE groups.
|Table 2: Characteristics of immune checkpoint inhibitors-related adverse events in patients with single and multiple immune checkpoint inhibitors-related adverse events|
Click here to view
Immunosuppressive treatment for immune-related adverse events
Among patients who developed irAEs, 145 (71.8%) needed immunosuppressive treatment [Table 3]. Steroid monotherapy was used to treat 108 (74.5%) of these patients, and steroid + infliximab combination was used to treat 37 (25.5%) patients. Patients with melanoma were treated significantly more often with a steroid + infliximab combination than with steroid monotherapy (P < 0.001). However, steroid monotherapy was used to treat patients with Stage IV malignancies significantly more often than was the steroid + infliximab combination (89.0% vs. 67.6%; P = 0.005). Steroid monotherapy was administered for a longer mean duration than was the steroid + infliximab combination although the difference was not statistically significant (4 months vs. 2 months; P = 0.198). The number of infection events was higher in patients who received steroid monotherapy (n = 50, 46.3%) than in patients who received steroid + infliximab combination (n = 13, 35.1%); however, again, the difference was not significant (P = 0.256).
|Table 3: Clinical characteristics of patients receiving steroid monotherapy or combination steroid + infliximab to treat immune checkpoint inhibitors-related adverse events|
Click here to view
Ipilimumab was used to treat melanoma more frequently than other cancers (melanoma, 70.3% vs. hematological malignancies, 20.9% and solid tumors, 30.0%; P < 0.001). No significant difference in the mean duration of ICPI treatment was observed between patients with different cancer types. IrAEs were significantly more common and required more often treatment with steroid + infliximab in patients with melanoma than in those with other cancers (both P < 0.001). The mean duration of steroid treatment did not differ significantly by cancer type (P = 0.218), but more patients with melanoma and solid tumors received long duration steroid treatment than did patients with hematological malignancies (P < 0.001). Significantly more patients with melanoma (19.6%) and solid tumors (15.3%) developed infections than did patients with hematological malignancies (5.8%; P < 0.001).
The mean duration of ICPI treatment was longer for patients with Stage IV cancers than for those with Stage III disease although the significance level was marginal (101 days vs. 58 days; P = 0.072). A higher proportion of patients with Stage III cancer developed irAEs than did patients with Stage IV cancer (P = 0.001). Moreover, irAEs in patients with Stage III cancers were more likely to be refractory to steroid treatment and to require infliximab treatment than were irAEs in patients with Stage IV disease (P < 0.001). Significantly more patients with Stage III cancer received a long course of steroid treatment than did patients with Stage IV cancer (P = 0.005).
Number of involved organs
In general, we found no significant differences between patients with single or multiple irAEs requiring immunosuppressive treatment [Table 4]. Diarrhea/colitis was the most common irAE requiring immunosuppressive treatment in both groups. The mean duration of ICPI treatment before the onset of the first irAE was similar: 78 days for patients with a single irAE and 62 days for patients with multiple irAEs (P = 0.414). Steroid monotherapy was used more often than steroid + infliximab to treat both single and multiple irAEs, and the mean duration of steroid treatment was comparable in both groups (P = 0.129). Most patients with both single and multiple irAEs received a long course (>30 days) of steroid treatment. The number of infection events was also comparable in patients with single and multiple irAEs requiring immunosuppressive treatment (P = 0.653).
|Table 4: Characteristics of immune checkpoint inhibitors-related adverse events requiring immunosuppressive therapy|
Click here to view
Immune checkpoint inhibitor type
The mean duration of ICPI treatment was significantly shorter for regimens containing ipilimumab than for nivolumab alone or pembrolizumab alone (P = 0.001) [Table 5]. Overall, patients who received regimens containing ipilimumab developed significantly more irAEs than did patients who received single-agent nivolumab or pembrolizumab (P < 0.001). GI tract irAEs were the most common irAEs in patients who received regimens containing ipilimumab (41.8%) or pembrolizumab (22.6%), whereas pneumonitis was more common in patients who received single-agent nivolumab (14.9%). The proportion of GI tract irAEs was higher in patients who received regimens containing ipilimumab or pembrolizumab than in patients who received single-agent nivolumab (P < 0.001). Immunosuppressive treatment with steroids alone or in combination with infliximab was more frequently used in patients who received regimens containing ipilimumab than in those who received other agents (P = 0.043 and P < 0.001, respectively). Infections were more frequently reported in patients receiving regimens containing ipilimumab than in patients receiving single-agent nivolumab or pembrolizumab (P = 0.001).
|Table 5: Patient clinical characteristics by immune checkpoint inhibitor|
Click here to view
Factors associated with the risk of developing immune-related adverse events
The results of multivariate logistic regression analysis to identify independent risk factors associated with irAE regardless of the need for immunosuppressive treatment are shown in [Table 6]. White patients had a higher risk of irAEs than did other patients (odds ratio [OR], 2.69; 95% confidence interval [CI], 1.49–2.69; P = 0.001). Cancer Stage III was associated with an increased risk of irAEs (OR, 5.26; 95% CI, 2.08–12.5; P < 0.001). Patients with melanoma had an increased risk of irAEs (OR, 2.33; 95% CI, 1.18–4.59; P = 0.015). The risk of irAEs was also higher in patients receiving ipilimumab as a monotherapy or in combination with nivolumab than in patients receiving other ICPIs (OR, 2.33; 95% CI, 1.31–4.16; P = 0.004). The duration of ICPI treatment did not affect the risk of irAEs (P = 1.000).
|Table 6: Multivariate logistic regression for immune checkpoint inhibitors-related adverse events risk|
Click here to view
Infectious adverse events associated with immunosuppression
In patients who received immunosuppressive treatment, 63 infectious adverse events were recorded. The most common type of immunosuppression-related infection was pneumonia (n = 18, 29%). Immunosuppressive treatment was complicated by the development of bacteremia or sepsis in 6 (10%) patients. Patients who received a short course (≤30 days) of steroid treatment had a significantly lower infection rate (30.4%) than did patients who received a long course of steroids (50.0%; P = 0.033) [Figure 1]a. Moreover, patients treated with a short course of a steroid + infliximab combination experienced a much lower rate of infection (18.7%) than did patients treated with a long course of steroid monotherapy (50.7%; P = 0.026) [Figure 1]b. Multivariate logistic regression analysis demonstrated that the duration of steroid use was associated with an independent risk of infection events related to immunosuppression (OR, 1.22; 95% CI, 1.05–1.41; P = 0.010) [Table 7]. Age, cancer type, number of irAEs, and infliximab use were not associated with infection events.
|Figure 1: Comparison of infection rates by duration of steroid use. (a) Long-duration (>30 days) versus short-duration (≤30 days) steroid use. (b) Long-duration steroid monotherapy versus short-duration combination of steroid and infliximab.|
Click here to view
|Table 7: Multivariate logistic regression model showing association of patient characteristics with risk of infection related to immunosuppressant use|
Click here to view
Overall survival estimates
The median length of follow-up was 15 months. Kaplan–Meier curves demonstrated that patients who developed irAEs had significantly longer median overall survival durations than did patients who did not (P < 0.001) [Figure 2]a, regardless of whether they had a single irAE or multiple irAEs (P = 0.001 and P < 0.001, respectively) [Figure 2]b and [Figure 2]c. Patients with mild irAE (s) that did not require immunosuppressive treatment also had significantly longer overall survival than did those without irAEs (P = 0.002) [Figure 2]d. Moreover, patients with three or more irAEs had longer overall survival than did patients with one or two irAEs (P = 0.010) [Figure 3]a. However, we found no significant difference in survival outcomes between patients with one irAE and those with two irAEs (P = 0.764) [Figure 3]b.
|Figure 2: Kaplan–Meier curves comparing overall survival estimates in patients with (a) immune-mediated adverse events versus no immune-related adverse events. (b) One immune-related adverse event versus no immune-related adverse events. (c) Multiple immune-related adverse events versus no immune-related adverse events. (d) Immune-related adverse events not treated with immunosuppressants versus no immune-related adverse events.|
Click here to view
|Figure 3: Kaplan–Meier curves comparing overall survival estimates by number of immune-related adverse events. (a) One or two immune-related adverse events versus three or more immune-related adverse events. (b) One immune-related adverse event versus two immune-related adverse events.|
Click here to view
Furthermore, patients with irAEs that required immunosuppressive treatment had longer median overall survival than did patients without irAEs (P < 0.001) [Figure 4]a. However, when only patients with irAEs were compared, immunosuppressive treatment did not affect survival durations (P = 0.726) [Figure 4]b. The median overall survival duration in patients who received steroid + infliximab combination was comparable to that in patients who received steroid monotherapy (P = 0.455) [Figure 4]c. Patients with a single GI tract irAE had significantly longer overall survival than did those with a single non-GI tract irAE (P = 0.029) [Figure 5].
|Figure 4: Kaplan–Meier curves comparing overall survival estimates by immune-related adverse event treatment. (a) Immune-related adverse event requiring immunosuppressive treatment versus no immune-related adverse event. (b) Immune-related adverse events with treatment versus immune-related adverse events without treatment. (c) Steroid monotherapy versus steroid + infliximab.|
Click here to view
|Figure 5: Kaplan–Meier curve comparing overall survival estimates by organ affected by immune-related adverse event (gastrointestinal versus nongastrointestinal).|
Click here to view
Survival analysis for patients with melanoma and solid tumors revealed that patients with Stage III cancer had longer overall survival than did patients with Stage IV disease although the statistical significance of this difference was marginal (P = 0.051) [Figure 6]a. In patients with irAEs, patients with Stage III cancers were not found to have longer overall survival than patients with Stage IV cancer (P = 0.132) [Figure 6]b. However, among patients with Stage IV cancer, the median overall survival duration of patients with irAEs was longer than that of patients without irAEs (P < 0.001) [Figure 6]c. In patients with melanoma, the occurrence of irAE was associated with better overall survival (P = 0.004) [Figure 6]d. Likewise, in patients with solid tumors, irAEs were predictors of longer survival duration (P = 0.005) [Figure 6]e. However, in patients with hematological malignancies, the survival difference was not significant between patients with irAE versus non-irAE (P = 0.347) [Figure 6]f. For patients with Stage IV melanoma, irAE independently predicted better overall survival (P = 0.007) [Figure 6]g.
|Figure 6: Kaplan–Meier curves comparing overall survival estimates in patients with solid tumors or melanoma by cancer stage and immune-related adverse event occurrence. (a) All patients, cancer Stage III versus Stage 4. (b) Patients with immune-related adverse event, cancer Stage III versus Stage IV. (c) Patients with Stage IV cancer: Immune-related adverse event versus no immune-related adverse event. (d) Patients with melanoma: immune-related adverse event versus no immune-related adverse event. (e) Patients with solid tumors: immune-related adverse event versus no immune-related adverse event. (f) Patients with hematological malignancy: immune-related adverse event versus no immune-related adverse event. (g) Patients with stage IV melanoma: immune-related adverse event versus no immune-related adverse event.|
Click here to view
| Discussion|| |
This is by far the largest-scale study with long-term follow-up conducted in a single center focusing on adverse events related to ICPI use in patients with solid or hematological malignancies. We found that patients who developed irAEs had longer overall survival durations than did patients who did not develop irAE(s), irrespective of the need for immunosuppressive treatment and the number of organs involved. In addition, we observed that steroid treatment for > 30 days was associated with a significantly increased rate of infection. Our findings corroborate those of previous studies conducted in patients with melanoma and nonsmall cell lung cancer although the definitive effect of irAEs on patients' long-term cancer outcomes is still under debate.,,,,,,, The data from our large sample size study were quite convincing regarding the remarkable impact of irAEs on overall survival duration.
We also reported that ipilimumab triggered more irAEs than other ICPIs, which is in concordance with other studies' results.,, This may explain why the median duration of ipilimumab treatment was shorter than that of other ICPIs. We recorded cancer stage only for solid tumors and melanomas because the staging systems used for hematological malignancies vary widely and cannot easily be correlated with solid tumor staging.
We found that even though many patients developed multiple irAEs, immunosuppressive treatment was not administered more often in patients with multiple irAEs than in those with single irAE. Diarrhea/colitis was the most common irAE observed in our patient population. Multiple irAEs could develop simultaneously or within a short period, which would be covered by a single complete course of immunosuppressive treatment or sequentially which would require a longer course of immunosuppressive treatment.
Overall, more patients with solid tumors and melanoma developed irAEs than did patients with hematological malignancies, likely to because ICPIs were used to treat these types of cancers earlier than they were used to treat hematological malignancies. The finding of increased risk of irAEs associated with Stage III cancer is anticipated. One of the reasons behind this observation is that patients with Stage III cancer received higher dose of CTLA-4 (10 mg/kg), as approved for clinical use, compared to patients with Stage IV cancer (3 mg/kg). Another reason is that PD-1 as monotherapy is approved for the treatment of patients with Stage IV cancer but not Stage III cancer. Furthermore, we speculate that the greater tumor burden of advanced, Stage IV cancers with their distant spread and extensive involvement could have mitigated the effect of ICPI treatment.
We found that patients with irAEs had longer overall survival duration than did patients without irAEs. This finding could have been a result of aggregating patients with various cancer types and stages that have variable disease courses as well as prognosis. With these potential confounding factors in mind, additional comparisons were conducted by stratifying patients according to cancer type and stage. Findings yielded from such stratification of our cohort were in concordance with our initial verdict of longer overall survival duration in all but one subset of patients, those with hematological malignancies. This could have been due to an underpowered analysis and should be taken into consideration by investigators while designing the future studies. These observations support our conclusion that irAE occurrence is a consistent independent predictor of longer survival regardless of cancer stage.
As immunosuppressive agents are currently the mainstay of treatment for irAEs, adverse events related to immunosuppressive treatment, especially infection, are a concern. Not surprisingly, we observed a significantly higher number of infections in patients treated with a steroid for > 30 days than in patients treated for 30 or fewer days. We compared the rates of infection in patients who received the two extremes of immunosuppressive treatment – a long course of steroids without infliximab or a short course of steroids with infliximab – and found that the difference became even more apparent. Indeed, the length of steroid treatment was the only independent factor that increased the risk of infection. These results provide clear guidance to balance the favorable effects on outcomes associated with irAEs against the need to minimize the risk of infection by introducing infliximab quickly when irAEs occur.
We detected significantly better survival outcomes in patients who developed irAE (s) than in those who did not, regardless of the need for immunosuppressive agents. Even patients who had only mild irAEs that did not require immunosuppressive treatment still had better outcomes than patients who did not have irAEs at all. This observation is distinctive to our analysis; most previous studies focused mainly on patients with irAEs that required treatment with immunosuppressants. Moreover, the need for, type and duration did not affect long-term survival in patients who developed irAEs. These findings suggest that immunosuppressive treatment is safe and does not compromise the favorable outcomes of ICPI treatment that are thought to be associated with irAEs.
We specifically compared the overall survival duration of patients with GI tract irAEs to that of patients with irAEs involving other organs and interestingly found that patients with GI tract irAEs had longer overall survival. However, we did not collect details about the grade of non-GI tract irAEs, so it is unclear whether this finding can be explained by differences in the severity of irAEs in the GI tract and other organs, although our sample size should have had enough power for this comparison. In addition, we found that patients with three or more irAEs had better outcomes than those with two or fewer irAEs. We suspect that not only the presence of an irAE, but also the higher level of severity associated with more extensive organ involvement, can predict a better long-term outcome.
There are some limitations to our study. First, because we included patients with many different cancer types to optimize our sample size, variation in the stage, disease characteristics, and course of different cancers could have confounded our results, particularly the overall survival analyses. Second, owing to the complexity of the criteria for evaluating progression-free survival, we did not analyze this outcome. Third, the treatment of irAEs with immunosuppression was mainly based on the general clinical condition of the patient, at the discretion of the primary treating physician, which could be different according to the standard practice of different departments.
| Conclusion|| |
Taken together, our study showed that irAE is an independent predictor for a better overall survival, irrespective of the need for immunosuppressive treatment or number of organs involved. Multiple organ involvement was associated with overall favorable survival. Our results suggest that early introduction of nonsteroidal immunosuppressive drugs such as infliximab can reduce the duration of steroid treatment in patients with irAEs, thereby balancing better cancer outcomes and a decreased risk of infection. Future prospective studies are required to thoroughly elucidate the association between risk factors for ICPI-induced multiorgan toxicities, tumor response to ICPIs, and long-term survival.
| Acknowledgments|| |
Medical editing of this paper was provided by the Department of Scientific Publications at MD Anderson Cancer Center.
Financial support and sponsorship
The authors declared no funding related to this study.
Conflicts of interest
The authors declared no conflicts of interest.
| References|| |
Patel MA. Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World J Immunol
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al.
Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer
Sondak VK, McArthur GA. Adjuvant immunotherapy for cancer: The next step. Lancet Oncol
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al.
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al.
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al.
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med
Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al.
Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med
Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol
Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. Cancer J
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS, et al.
Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res
Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al.
Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol
Edge SB, Compton CC. The American joint committee on cancer: The 7th
edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol
Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al.
Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: A prospective cohort study. J Thorac Oncol
Owen DH, Wei L, Villalona-Calero MA, Bertino EM, He K, Shields PG, et al
. Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC). J Clin Oncol
Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol
Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al.
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res
Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al.
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol
Cousin S, Italiano A. Molecular pathways: Immune checkpoint antibodies and their toxicities. Clin Cancer Res
Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al.
Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev
Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7]
|This article has been cited by|
||Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
| ||Tenglong Tang,Hamzah Abu-Sbeih,Wenyi Luo,Phillip Lum,Wei Qiao,Robert S. Bresalier,David M. Richards,Yinghong Wang |
| ||Scandinavian Journal of Gastroenterology. 2019; : 1 |
|[Pubmed] | [DOI]|
||Something old, something new: liver injury associated with Total parenteral nutrition therapy and immune checkpoint inhibitors
| ||Cherise Meyerson,Bita V. Naini |
| ||Human Pathology. 2019; |
|[Pubmed] | [DOI]|
||Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
| ||Hamzah Abu-Sbeih,Faisal S. Ali,Abdul Rafeh Naqash,Dwight H. Owen,Sandipkumar Patel,Gregory A. Otterson,Kari Kendra,Biagio Ricciuti,Rita Chiari,Andrea De Giglio,Joseph Sleiman,Pauline Funchain,Beatriz Wills,Jiajia Zhang,Jarushka Naidoo,Jessica Philpott,Jianjun Gao,Sumit K. Subudhi,Yinghong Wang |
| ||Journal of Clinical Oncology. 2019; 37(30): 2738 |
|[Pubmed] | [DOI]|
||Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
| ||Catherine R. Sears,Tobias Peikert,Jennifer D. Possick,Jarushka Naidoo,Mizuki Nishino,Sandip P. Patel,Philippe Camus,Mina Gaga,Edward B. Garon,Michael K. Gould,Andrew H. Limper,Philippe R. Montgrain,William D. Travis,M. Patricia Rivera |
| ||American Journal of Respiratory and Critical Care Medicine. 2019; 200(6): e31 |
|[Pubmed] | [DOI]|
||Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
| ||Ronald Anderson,Annette J. Theron,Bernardo L. Rapoport |
| ||Frontiers in Immunology. 2019; 10 |
|[Pubmed] | [DOI]|
| ||Tara Menon,Anita Afzali |
| ||Current Treatment Options in Gastroenterology. 2019; |
|[Pubmed] | [DOI]|
||Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy
| ||Hamzah Abu-Sbeih,Tenglong Tang,Faisal S. Ali,Wenyi Luo,Sattva S. Neelapu,Jason R. Westin,Pablo C. Okhuysen,Wai Chin Foo,Jonathan L. Curry,David M. Richards,Phillip S. Ge,Yinghong Wang |
| ||American Journal of Clinical Oncology. 2019; 42(10): 789 |
|[Pubmed] | [DOI]|